Physiological Steps Doctrine

A. Torrance
{"title":"Physiological Steps Doctrine","authors":"A. Torrance","doi":"10.15779/Z38PQ5Z","DOIUrl":null,"url":null,"abstract":"In vivo conversion is a process, often metabolic in nature, wherein one substance, usually a chemical compound, is altered significantly by physiological pathways in the body into one or more different substances. For example, when a patient ingests a therapeutic drug, that drug is often converted by the natural physiology of the digestive system into one or more chemically different metabolites. The end products of in vivo conversion sometimes possess therapeutic efficacy. Many patent applications have claimed such therapeutic metabolites, either as compositions per se or as parts of methods of treatment. Although the USPTO has granted patent claims to such products generated by in vivo conversion of ingested drugs, and courts have noted the eligibility of such products as patentable subject matter, never has a United States court of final appeal upheld such a patent claim as valid, enforceable, and infringed. The unanimity of results in cases involving patent infringement triggered by in vivo conversion is striking. In fact, its very improbability suggests a common underlying explanation for why in vivo conversion does not ever seem to trigger patent infringement. Explanations based on inherency or a lack of evidence provide a satisfactory explanation for only a minority of in vivo cases. The Physiological Steps Doctrine, which suggests that products and processes of in vivo conversion are unpatentable subject matter under U.S. patent law, offers an explanation that spans all in vivo conversion cases. Though the rationales offered to explain the results in a number of in vivo conversion cases are suggestive, there are several advantages for a more explicit recognition of the Physiological Steps Doctrine. Consistent with much international, European, and U.S. patent law, the Physiological Steps Doctrine provides a theoretical underpinning to explain the results in cases involving products and processes of in vivo conversion. This theoretical underpinning not only has explanatory power for interpreting previous case law but is also useful in predicting the outcome of future in vivo conversion cases. In addition, the Physiological Steps Doctrine increases the understanding of where inventions involving human beings, and the biological products and processes thereof, fit within the spectrum of patentable subject matter.","PeriodicalId":281709,"journal":{"name":"Intellectual Property Law eJournal","volume":"11 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2009-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Intellectual Property Law eJournal","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15779/Z38PQ5Z","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 2

Abstract

In vivo conversion is a process, often metabolic in nature, wherein one substance, usually a chemical compound, is altered significantly by physiological pathways in the body into one or more different substances. For example, when a patient ingests a therapeutic drug, that drug is often converted by the natural physiology of the digestive system into one or more chemically different metabolites. The end products of in vivo conversion sometimes possess therapeutic efficacy. Many patent applications have claimed such therapeutic metabolites, either as compositions per se or as parts of methods of treatment. Although the USPTO has granted patent claims to such products generated by in vivo conversion of ingested drugs, and courts have noted the eligibility of such products as patentable subject matter, never has a United States court of final appeal upheld such a patent claim as valid, enforceable, and infringed. The unanimity of results in cases involving patent infringement triggered by in vivo conversion is striking. In fact, its very improbability suggests a common underlying explanation for why in vivo conversion does not ever seem to trigger patent infringement. Explanations based on inherency or a lack of evidence provide a satisfactory explanation for only a minority of in vivo cases. The Physiological Steps Doctrine, which suggests that products and processes of in vivo conversion are unpatentable subject matter under U.S. patent law, offers an explanation that spans all in vivo conversion cases. Though the rationales offered to explain the results in a number of in vivo conversion cases are suggestive, there are several advantages for a more explicit recognition of the Physiological Steps Doctrine. Consistent with much international, European, and U.S. patent law, the Physiological Steps Doctrine provides a theoretical underpinning to explain the results in cases involving products and processes of in vivo conversion. This theoretical underpinning not only has explanatory power for interpreting previous case law but is also useful in predicting the outcome of future in vivo conversion cases. In addition, the Physiological Steps Doctrine increases the understanding of where inventions involving human beings, and the biological products and processes thereof, fit within the spectrum of patentable subject matter.
生理步骤学说
体内转化是一个过程,在本质上通常是代谢,其中一种物质,通常是一种化合物,在体内通过生理途径显着改变为一种或多种不同的物质。例如,当患者摄入治疗药物时,该药物通常通过消化系统的自然生理学转化为一种或多种化学上不同的代谢物。体内转化的最终产物有时具有治疗功效。许多专利申请要求将这种治疗性代谢物作为组合物本身或作为治疗方法的一部分。尽管美国专利商标局(USPTO)已经授予了由摄入药物的体内转化产生的此类产品的专利权利要求,法院也注意到此类产品作为可专利客体的资格,但从未有美国终审法院支持此类专利权利要求为有效的、可执行的和侵权的。在涉及体内转化引发的专利侵权案件中,结果的一致是惊人的。事实上,它的不可能性暗示了一个共同的潜在解释,为什么体内转化似乎从来没有引发专利侵权。基于遗传或缺乏证据的解释只能对少数体内病例提供令人满意的解释。生理步骤原则(Physiological Steps Doctrine)认为,根据美国专利法,体内转化的产品和过程是不可专利的客体,它提供了一种涵盖所有体内转化案例的解释。虽然在一些体内转化案例中提供的解释结果的基本原理是暗示性的,但更明确地承认生理步骤原则有几个优点。与许多国际、欧洲和美国专利法一致,生理步骤原则提供了一个理论基础来解释涉及体内转化产品和过程的情况下的结果。这一理论基础不仅对解释以往的判例法具有解释力,而且对预测未来体内转换案件的结果也很有用。此外,生理步骤原则增加了对涉及人类的发明及其生物产品和过程在可获得专利的主题范围内的位置的理解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信